8,382 Shares in Bristol-Myers Squibb (NYSE:BMY) Acquired by Decker Retirement Planning Inc.

Decker Retirement Planning Inc. purchased a new position in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 8,382 shares of the biopharmaceutical company's stock, valued at approximately $474,000.

Several other institutional investors have also recently made changes to their positions in the company. Cohen Investment Advisors LLC raised its holdings in shares of Bristol-Myers Squibb by 2.6% in the 4th quarter. Cohen Investment Advisors LLC now owns 8,802 shares of the biopharmaceutical company's stock valued at $498,000 after purchasing an additional 221 shares in the last quarter. Ritholtz Wealth Management raised its stake in Bristol-Myers Squibb by 65.2% in the fourth quarter. Ritholtz Wealth Management now owns 39,389 shares of the biopharmaceutical company's stock worth $2,228,000 after buying an additional 15,546 shares in the last quarter. Carnegie Investment Counsel lifted its holdings in Bristol-Myers Squibb by 3.7% during the fourth quarter. Carnegie Investment Counsel now owns 33,435 shares of the biopharmaceutical company's stock worth $1,891,000 after buying an additional 1,193 shares during the period. Mirador Capital Partners LP boosted its position in Bristol-Myers Squibb by 1.7% during the 4th quarter. Mirador Capital Partners LP now owns 47,354 shares of the biopharmaceutical company's stock valued at $2,678,000 after acquiring an additional 774 shares in the last quarter. Finally, IFS Advisors LLC increased its holdings in shares of Bristol-Myers Squibb by 359.3% in the 4th quarter. IFS Advisors LLC now owns 767 shares of the biopharmaceutical company's stock valued at $43,000 after acquiring an additional 600 shares during the period. Hedge funds and other institutional investors own 76.41% of the company's stock.

Bristol-Myers Squibb Stock Performance

NYSE BMY traded up $0.10 on Friday, reaching $56.48. 7,886,595 shares of the company's stock traded hands, compared to its average volume of 9,115,889. The stock has a 50 day moving average price of $57.45 and a 200-day moving average price of $51.79. The firm has a market cap of $114.54 billion, a price-to-earnings ratio of -15.74, a P/E/G ratio of 1.95 and a beta of 0.45. The company has a debt-to-equity ratio of 2.83, a quick ratio of 1.09 and a current ratio of 1.24. Bristol-Myers Squibb has a fifty-two week low of $39.35 and a fifty-two week high of $61.08.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 EPS for the quarter, topping the consensus estimate of $1.49 by $0.31. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. The firm had revenue of $11.89 billion for the quarter, compared to analyst estimates of $11.26 billion. During the same period last year, the company earned $2.00 earnings per share. Bristol-Myers Squibb's revenue for the quarter was up 8.4% compared to the same quarter last year. Equities research analysts predict that Bristol-Myers Squibb will post 0.93 EPS for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, February 3rd. Investors of record on Friday, January 3rd will be given a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a yield of 4.39%. The ex-dividend date is Friday, January 3rd. This is a positive change from Bristol-Myers Squibb's previous quarterly dividend of $0.60. Bristol-Myers Squibb's dividend payout ratio (DPR) is currently -69.08%.

Insider Buying and Selling at Bristol-Myers Squibb

In related news, EVP Samit Hirawat purchased 1,830 shares of the business's stock in a transaction that occurred on Friday, November 1st. The stock was bought at an average price of $54.67 per share, with a total value of $100,046.10. Following the acquisition, the executive vice president now owns 62,109 shares in the company, valued at $3,395,499.03. The trade was a 3.04 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Phil M. Holzer sold 700 shares of the stock in a transaction on Monday, November 4th. The shares were sold at an average price of $55.62, for a total transaction of $38,934.00. Following the transaction, the senior vice president now directly owns 11,760 shares in the company, valued at approximately $654,091.20. The trade was a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.09% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages recently weighed in on BMY. UBS Group lifted their target price on Bristol-Myers Squibb from $50.00 to $54.00 and gave the company a "neutral" rating in a research note on Wednesday, October 9th. Truist Financial boosted their price objective on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a "buy" rating in a research note on Wednesday, January 8th. Cantor Fitzgerald restated a "neutral" rating and issued a $50.00 target price on shares of Bristol-Myers Squibb in a research note on Friday, October 18th. BMO Capital Markets upped their price target on Bristol-Myers Squibb from $57.00 to $61.00 and gave the stock a "market perform" rating in a research report on Tuesday, November 12th. Finally, Bank of America reissued a "neutral" rating and issued a $63.00 price objective on shares of Bristol-Myers Squibb in a research report on Tuesday, December 10th. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $56.27.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.